Poster zum Thema "Migraine"

Zurück
  • P1
The TRPA1 pain pathway is a target for multiple environmental pollutants: Possible relevance for migraine
  • P10
Pharmacological characterization of gepants in human and porcine vasculature
  • P103
Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
  • P104
A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine
  • P105
Sustained Response to Atogepant in Individuals with Episodic Migraine: Post Hoc Analyses of 12- and 52-Week Phase 3 Trials
  • P106
Post-hoc Analysis Evaluating Safety of Atogepant in ADVANCE & Open-Label Extension Participants with Cardiovascular Risk Factors
  • P107
Cut-off value for Tampa Scale for Kinesiophobia in migraine patients
  • P108
A retrospective real-life multicenter study on concurrent oral preventives in patients with chronic migraine treated with botulinum toxin
  • P109
Impact of Eptinezumab on Patient-Reported Outcomes in Patients With Prior Preventive Treatment Failures
  • P110
Subsequent Response to Atogepant in Individuals with Episodic Migraine after an Initial Inadequate Response: Post Hoc Analysis of a 12-week Phase 3 Trial
  • P111
Eptinezumab for Migraine Prevention in Patients with 2-4 Prior Treatment Failures: DELIVER Subpopulation Analysis
  • P112
Efficacy and Safety of Eptinezumab for Migraine Prevention in Patients With 2–4 Prior Preventive Treatment Failures
  • P113
Psychopathological disorders in chronic migraine: is there an association with the endocannabinoid system?
  • P114
Real-World Persistence and Costs Among Patients With Chronic Migraine Treated With OnabotulinumtoxinA or CGRP mAbs: A Retrospective Claims Analysis Study
  • P115
Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Triptan Treatment Experience
  • P116
Adenosine causes short-lasting vasodilation and headache, but not migraine attacks in migraine patients: A randomized clinical trial
  • P117
Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
  • P118
Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: methods and global findings for diagnosis rates and care
  • P119
Eptinezumab Improved Work Productivity in Adults With Migraine and Prior Preventive Treatment Failures: Results From the Randomized, Double-Blind, Placebo-Controlled DELIVER Study
  • P120
Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific Quality of Life in Responders to Atogepant: A Post Hoc Analysis
  • P120a
Evaluation of PREEMPT fixed-dose, fixed-site and follow the pain treatment paradigms in the PREDICT Study
  • P121
The virtual "Enfacement Illusion" on pain perception in patients suffering from chronic migraine: Preliminary data from a randomized controlled trial
  • P122
Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study
  • P123
Medication Preference, Satisfaction, and Clinical Improvement Among Adults Receiving Long-Term Treatment With Rimegepant for Migraine
  • P124
Characterizing gaps in preventive treatment of migraine: global results from the CaMEO-International study
  • P125
Concomitant treatment of anti-CGRP and botulinum toxin in resistant migraine, is it useful for our patients?
  • P126
The effect or resveratrol in ex vivo and behavioral rat models of migraine
  • P127
Is migraine causally linked to inflammatory bowel disease or coeliac disease? A Mendelian randomisation study
  • P128
Medication overuse and patient-reported outcome of OnabotulinumtoxinA treatment in Chronic Migraine
  • P129
Atogepant for the Preventive Treatment of Chronic Migraine in Europe: Results From the PROGRESS Study
  • P130
Additional effects of pain neuroscience education combined with physiotherapy on the headache frequency of adult patients with migraine – a randomized controlled trial
  • P131
Assessing Hypersensitivity, Cortical Hyperexcitability, and Habituation in Migraine, according to Age and Disease Severity, using Visual Evoked Potentials during Pattern-Reversal Stimulation
  • P132
Effects of vitamin B1, B6, and B12 on serum levels of CGRP, endothelial nitric-oxide synthase, homocysteine, and headache characteristics in women with episodic migraine
  • P133
Quantifying aversion thresholds to light, sound, smell, and touch in migraine: A longitudinal study in migraine and non-headache controls
  • P134
Negative impact of under-diagnosed migraine in university students in Slovakia
  • P135
Change in Migraine Diagnosis After Preventive Treatment With Eptinezumab: Post Hoc Analysis of the PROMISE Studies
  • P136
Hormonal treatment for menstrual migraine: rationale and protocol of the WHAT!-Trial
  • P136a
Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
  • P137
Identification of crystal-clear days in migraine using data of a nation-wide population-based study
  • P137a
Long-Term Treatment With Lasmiditan in Patients With Migraine: Results From the Open-Label Extension of the CENTURION Study
  • P138
Patterns of use of monoclonal antibodies for the preventive treatment of migraine: Results from the OVERCOME (EU) study
  • P139
Cardiovascular risk factors and migraine: Results from the population-based Rotterdam study
  • P140
A prospective evaluation of neurological presentations to a National Neuro-Behçet Clinic in the UK- Migraine is the commonest neurological complaint in Behçet's disease
  • P141
Safety and tolerability of atogepant: a post hoc analysis of pooled data from four clinical trials
  • P142
Effect of atogepant on Migraine-Specific Quality of Life Questionnaire and Headache Impact Test-6 in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
  • P143
Effect of atogepant on the Activity Impairment in Migraine–Diary and Work Productivity and Activity Impairment Questionnaire in a 12-week, double-blind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
  • P144
Erenumab as a first line preventive treatment for episodic migraine in Spain: a cost-effectiveness analysis.
  • P145
Impact of migraine attack accompanying symptoms in treatment response to anti-CGRP monoclonal antibodies treatment and their evolution after 6 months
  • P146
Mapping Migraine Minds: A cross-sectional survey to compare the difference in the level of treatment expectations and satisfaction for migraine among Indian male & female patients
  • P147
Migraine, chronic neck pain and endurance muscle cervical test – a controlled study
  • P148
Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study
  • P149
Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Study
  • P150
Onabotulinum toxinA for unremitting chronic migraine: assessment of muscle function and strength, efficacy and safety after 10 years of continuous treatment.
  • P151
Long-term Effectiveness and Safety of Erenumab in patients with Migraine: a Systematic Review and Single-Arm Meta-analysis
  • P152
Prospective evaluation of migraine premonitory symptoms during the 30 days period
  • P153
Prevalence of sinonasal symptoms in migraine without aura (results from Migraine in Poland - a nationwide cross-sectional survey)
  • P154
Evaluation of a mandatory drug holiday during treatment with monoclonal antibodies targeting the cgrp pathway: a patient survey
  • P155
Use of CGRP monoclonal antibodies and patient-reported improvement: Results from the OVERCOME (EU) study
  • P156
Total tau concentrations are increased in blood serum of migraine patients: A cross-sectional case-control study
  • P157
Disconnectome of the Migraine Brain: A Model of Migraine as "Connectopathy"
  • P158
Changes in Sensitization and Habituation Measured by Algometry in Chronic Migraine Patients Treated with Onabotulinumtoxin A
  • P159
Mapping Migraine Minds: A cross-sectional survey to compare the difference in burden of migraine among Indian male & female patients
  • P160
Whole-brain functional connectome alterations in patients with migraine
  • P161
Interictal IgE and tryptase levels in episodic and chronic migraine
  • P162
Efficacy and safety of once monthly subcutaneous erenumab 70 mg in adult chronic migraine patients (primary analysis): Indian sub analysis from Global DRAGON study
  • P163
Subjective Tinnitus in Pediatric and Adolescent Migraine Versus Other Primary Headaches – a Prospective, Comparative Study
  • P164
Influence of Neck Pain in Response to Cervical Spine Manual Palpation on Neck Proprioception and Muscle Endurance of Migraine Patients and Controls
  • P165
Association Between Migraine and Transient Global Amnesia: An Inpatient Sample Analysis
  • P166
Gradually shifting clinical phenomics in migraine spectrum: A Cross-sectional, Multicenter study of 5438 patients
  • P167
Characterization of the spectral content of resting-state electroencephalographic activity in chronic migraine female patients
  • P168
Impact of air pollution exposure on headache onset in migraine patients
  • P169
A Cohort Study Comparing Melatonin-users with Non-users in the treatment of Migraine Headaches.
  • P170
Epilepsy in Migraine Aggravates the Cognitive Disorders
  • P171
Impact of migraine in Indian housewives: A subset analysis from Mapping Migraine Minds study- A cross-sectional study to compare the difference in burden of migraine among Indian males & females
  • P172
The effect of botulinum toxin on anxiety and depression scales in chronic and high frequency migraneurs
  • P173
Intravenous lidocaine and ketamine infusions for headache disorders: a retrospective cohort study
  • P174
HEADWORK as innovative tool for monitoring MABs efficacy in migraine and their influence on work activity.
  • P175
Optimization of Acute Treatment in Migraine Patients Treated with Monoclonal Antibodies Acting on the CGRP Pathway
  • P176
Personalized Low-Glycemic Nutrition for the Prophylaxis of Migraine: Real World Data from two Prospective Studies using a Digital Therapeutic
  • P177
Iprazochrome and codeine – unlikely winners in migraine treatment in Poland. Targeting areas for improvement in migraine treatment (results from Migraine in Poland - a nationwide cross-sectional survey)
  • P178
Alternative Indirect Treatment Comparisons for Eptinezumab in Migraine Prevention
  • P179
Clinical pattern and response to treatment of predominant posterior migraine
  • P180
Classification of the pain curve and semiology of a migraine crisis
  • P181
Evolution of practice guidelines for the treatment of acute migraine with Paracetamol (Acetaminophen)
  • P182
Craniocervical Flexion Test in patients with migraine: discriminatory validity and accuracy
  • P183
Prevalence, disease profile, treatment patterns and burden of migraine in India: An internet-based survey
  • P184
Use of Carbamazepine in Patients with Migraine-Comorbid Epilepsy in The Uzbek Population
  • P186
Treatment of Migraine in children and adolescents
  • P187
Vitamins and migraine? Is it a matter? The possible effects and suggested pathophysiology
  • P188
Vestibular Migraine: Management differences between General Neurology and Neuro-Otology
  • P190
Prediction of a migraine crisis in real-time using a wearable device
  • P191
Utility of machine-learning based models to predict 30%, 50% and 75% response to anti-CGRP response in patients with migraine: a multicenter Spanish study
  • P195
Machine prescription for chronic migraine
  • P198
@TrialMigraine: A Daily Migraine Clinical Trials Tracker
  • P2
Functional responses in a patient-specific iPSC-derived vascular model: a novel approach to study migraine
  • P201
The structure and organization of headache differential diagnoses: A Pilot Study of Subset Relationships between Differentials in ICHD3
  • P202
A comprehensive list of prevention medications without drug-drug interactions can be generated from DrugBank and FAERS
  • P206
How to sequentially try all possible "pick two" combinations of abortive and/or prevention medications: an exploration in hamiltonian cycles in headache
  • P217
Idiopathic intracranial hypertension presenting with migraine phenotype is associated with unfavorable headache outcome
  • P227
Sleep Disorders in Pediatric Migraine: a questionnaire-based study
  • P23
Coexistence of migraine and cluster headache - is it more than just a coincidence?
  • P230
Cutaneous allodynia in pediatric and adolescent patients and their mothers – a comparative study
  • P232
Long-term effects of pandemic of Covid-19 on clinical features and psychological symptoms in adolescents with migraine
  • P234
The influence of anxiety and depression on headache in adolescent migraineurs: A case-control study
  • P235
Abnormal eye movements in a girl with Vestibular migraine: a case report and review of the literature
  • P236
Allodynia and muscle sensitization of cervical muscles are not associated with neck range of motion in children and adolescents diagnosed with migraine
  • P238
Does symptomatic treatment help children and adolescents with chronic migraine?
  • P239
Angelman syndrome and cyclic vomiting syndrome: a new potential association – Not all the vomiting are only vomiting!
  • P240
Clinical characteristics of children and adolescents with primary and secondary headaches in the tertiary-level of a public hospital in Brazil
  • P241
Sars-Cov-2 and Headache in Children and adolescents
  • P242
Prevalence of neck pain in migraine: A systematic review and meta-analysis
  • P245
Characterizing opioid use in a Dutch cohort with migraine
  • P246
The association of innate and adaptive immunity with migraine in The Rotterdam Study: a population-based cohort study
  • P249
Visual aura in non-migrainous headache: a population study
  • P256
Migraine Should Be First Focus on Headache Education in the Middle East, Asia, and Africa: A subgroup analysis of the Head-MENAA Study
  • P257
Switching from anti-CGRP-receptor mAb (erenumab) to an anti-CGRP-molecule mAbs (fremanezumab) in chronic migraine: results of a real-world study
  • P258
REAL-WORLD FREMANEZUMAB EXPERIENCE FROM HEADACHE CLINIC IN MOSCOW
  • P259
Discontinuation after one-year of treatment with anti-CGRP antibodies did not provide long-term sustained response without therapy
  • P260
Anti-CGRP monoclonal antibodies and peripheral sensitization: a study on Pressure Pain Threshold in migraineurs
  • P262
Is it worth switching monoclonal antibodies?
  • P263
Study on the presence of comorbidities in a series of 200 patients with migraine and their influence on the effectiveness of fremanezumab.
  • P264
Predictors of galcanezumab response in Korean patients with migraine
  • P265
Can We Descriminate Migraine Susceptibile to CGRP Antagonism?
  • P266
Interim Analysis on the Effectiveness of Fremanezumab for the Preventive Treatment of Migraine: The Observational PEARL Study
  • P267
Response patterns in migraine patients in prophylactic treatment with different anti-CGRP pharmacological blockade systems
  • P268
Effect of Galcanezumab in Migraine and Concomitant Medication Overuse Headache Without Prior Drug Withdrawal
  • P269
Factors associated with favorable outcome in galcanezumab treatment for chronic migraine: A clinic-based prospective study
  • P270
Past Preventive Migraine Treatment in Patients Initiating Fremanezumab in Clinical Practice: Interim Data from the PEARL Study
  • P272
Descriptive study on the presence, treatment and evolution of comorbidities in a series of 200 migraine patients treated with fremanezumab.
  • P273
Response to fremanezumab in migraine patients with and without prior aCGRP mAbs - preliminary data from the FINESSE study
  • P274
Could Symptom Severity Predict the Response to Anti-Cgrp Monoclonal Antibodies in Migraine?
  • P276
Prevalence of migraine according to Migraine Screening-Questionnaire (MS-Q) and headache characteristics in patients with inflammatory bowel disease (IBD)
  • P277
Influence of migraine and migraine aura on the prescription of hormonal contraception in German outpatient gynecological clinics
  • P278
Sex differences in migraine attack characteristics: a longitudinal E-diary study
  • P279
Ketogenic diet for migraine prevention: an effective option beyond weight loss
  • P29
Impact of migraine on the presentation of reversible cerebral vasoconstriction syndrome
  • P3
Relevance of mouse vasculature in investigating side-effects of anti-migraine medications.
  • P38
Characterization of adult patients with status migrainosus in a tertiary hospital in Colombia, 2019-2021
  • P39
Implementing a digital treatment solution for headache patients – a pilot study.
  • P4
Calcitonin gene-related peptide receptor antagonist BIBN4096BS regulates synaptic transmission in the vestibular nucleus and improves vestibular function via PKC/ERK/CREB pathway in an experimental chronic migraine rat model
  • P40
PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine
  • P42
Prevalence of temporomandibular disorders with comorbid migraine: A retrospective study in a 5-year period 
  • P47
Neurovascular Orofacial Pain – A Diagnostic Dilemma
  • P5
An open-source electrophysiology system to explore visual evoked potentials in migraine
  • P50
Real-world Reductions in Monthly Migraine Days and Migraine-Related Healthcare Resource Utilization in UK Patients Using Fremanezumab
  • P51
Anti-CGRP mAbs in a difficult to treat migraine population. Efficacy and safety.
  • P52
The efficacy of CGRP monoclonal antibodies – an Australian experience
  • P53
Use of non-pharmacological therapies in individuals with migraine eligible for treatment with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP)-signaling: a single-center cross-sectional observational study
  • P54
Role of Monoclonal Antibodies Against the Calcitonin Gene-Related Peptide or Receptor (CGRP-Mabs) for Chronic Migraine Prevention: A Critical Review
  • P55
Real Life Experience: Use of CGRP Inhibitors in Patients Older than 55 Years Old, are they Safe and Effective?
  • P56
Real life experience and learning curve of Galcanezumab in migraine. Galca-only Consortium
  • P59
Investigating the Long-Term Efficacy of Calcitonin Gene Related Peptide Monoclonal Antibodies
  • P6
Effects of caffeine on intracranial pressure and pain perception in freely moving rats
  • P61
Diagnostic utility of T2*-weighted GRE in migraine with aura attack. The cortical veins sign
  • P62
Emotional processing differences between migraine and tension-type headache subjects – an fMRI study
  • P63
Dynamic functional connectivity in migraine during the interictal phase: a resting-state fMRI study
  • P64
Reliable posterior insula–operculum region gray matter volume alterations in vestibular migraine
  • P67
White-matter microstructural changes in episodic menstrual migraine compared with hormonal controls
  • P68
Neuroimaging Utilization in Telemedicine Relative to In-Person Initial Visits for Migraine and Headache at a Tertiary Headache Center: A One-Year Analysis
  • P73
Clinical manifestations and impact of SARS-CoV-2 infections and vaccines in patients with migraine
  • P77
Effect of Covid 19 Infection on Episodic Migraine Patients in Saudi Populations and Role of Vaccination
  • P91
Glibenclamide posttreatment does not inhibit levcromakalim induced headache: A randomized clinical trial
  • P93
Recording pre-ictal migraine changes in cortical responsivity using EEG in a patient's home environment
  • P94
Vestibular signs in experimentally induced migraine attacks: a post-hoc, exploratory analysis